Ablynx Announces Warrant Exercise
Regulated Information
(firmenpresse) - GHENT, BELGIUM -- (Marketwire) -- 01/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 61,812 common shares have been issued by the Company in exchange for EUR 329,619.51 as the result of the exercise of warrants by some employees and consultants of the Company.
As a result of this transaction, Ablynx now has 43,779,197 shares outstanding.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on .
Press release (PDF):
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193
+32 (0)473 39 50 68
e:
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:
Follow us on Twitter (at)AblynxABLX
Mary-Jane Elliott
Amber Bielecka
Claire Dickinson
t: +44 207 920 2330
e:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.01.2013 - 11:41 Uhr
Sprache: Deutsch
News-ID 1188934
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
GHENT, BELGIUM
Phone:
Kategorie:
Healthcare
Anmerkungen:
Diese Pressemitteilung wurde bisher 137 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ablynx Announces Warrant Exercise
"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
